First Trust Advisors LP Grows Stock Holdings in Astera Labs, Inc. $ALAB

First Trust Advisors LP boosted its stake in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 140.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 271,041 shares of the company’s stock after buying an additional 158,275 shares during the quarter. First Trust Advisors LP owned 0.16% of Astera Labs worth $53,070,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Assetmark Inc. boosted its stake in shares of Astera Labs by 374.1% during the 3rd quarter. Assetmark Inc. now owns 128 shares of the company’s stock worth $25,000 after acquiring an additional 101 shares in the last quarter. Clearstead Trust LLC increased its stake in Astera Labs by 46,100.0% in the 2nd quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock valued at $42,000 after purchasing an additional 461 shares in the last quarter. Advisors Asset Management Inc. raised its holdings in Astera Labs by 68.6% during the second quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock worth $43,000 after purchasing an additional 194 shares during the last quarter. Manchester Capital Management LLC raised its holdings in Astera Labs by 141.5% during the second quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock worth $44,000 after purchasing an additional 283 shares during the last quarter. Finally, Whittier Trust Co. purchased a new stake in Astera Labs during the third quarter worth $55,000. 60.47% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on ALAB. Loop Capital started coverage on Astera Labs in a report on Thursday, March 5th. They issued a “buy” rating and a $250.00 target price on the stock. Barclays set a $165.00 price target on Astera Labs in a research note on Thursday, January 15th. Northland Securities increased their price objective on shares of Astera Labs from $175.00 to $195.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. BNP Paribas Exane initiated coverage on shares of Astera Labs in a report on Thursday, November 20th. They set an “outperform” rating for the company. Finally, Jefferies Financial Group restated a “buy” rating on shares of Astera Labs in a research report on Wednesday, December 3rd. Fifteen research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $195.89.

Astera Labs Stock Up 7.1%

NASDAQ ALAB opened at $124.71 on Thursday. Astera Labs, Inc. has a fifty-two week low of $47.13 and a fifty-two week high of $262.90. The stock has a market cap of $21.23 billion, a price-to-earnings ratio of 102.22, a price-to-earnings-growth ratio of 2.29 and a beta of 1.74. The business has a fifty day moving average of $150.00 and a 200-day moving average of $168.89.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings data on Tuesday, February 10th. The company reported $0.58 EPS for the quarter, beating analysts’ consensus estimates of $0.51 by $0.07. The business had revenue of $270.58 million for the quarter, compared to analyst estimates of $249.46 million. Astera Labs had a return on equity of 16.12% and a net margin of 25.70%.The business’s revenue for the quarter was up 91.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.37 earnings per share. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. As a group, analysts anticipate that Astera Labs, Inc. will post 0.34 EPS for the current year.

Insider Buying and Selling

In other news, General Counsel Philip Mazzara sold 10,000 shares of Astera Labs stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $117.47, for a total transaction of $1,174,700.00. Following the completion of the sale, the general counsel directly owned 128,084 shares in the company, valued at $15,046,027.48. The trade was a 7.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Jitendra Mohan sold 94,971 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $123.81, for a total transaction of $11,758,359.51. Following the completion of the transaction, the chief executive officer directly owned 1,452,739 shares of the company’s stock, valued at approximately $179,863,615.59. This represents a 6.14% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 224,292 shares of company stock worth $27,676,069 in the last 90 days. 12.50% of the stock is currently owned by corporate insiders.

About Astera Labs

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.